MedTrace Logo

INTERACT Stomach-II

NCT07133490 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2025-08-21

No results posted yet for this study

Summary

This is a phase II study conducted in three hospitals in the Netherlands (Erasmus MC in Rotterdam, Catharina Hospital in Eindhoven, and the Netherlands Cancer Institute in Amsterdam). A total of 49 patients will take part. The aim is to test whether a new combination treatment is feasible for patients with gastric peritoneal metastases (PM). The treatment includes chemotherapy (intraperitoneal irinotecan and standard systemic therapy such as CAPOX or FOLFOX), and may also include nivolumab or trastuzumab, depending on biomarker results.

Conditions

  • Peritoneal Metastases From Gastric Cancer

Interventions

DRUG

intraperitoneal chemotherapy

Through a peritoneal access port, irinotecan will be administered at the same time as systemic (chemo)therapy

Sponsors & Collaborators

  • Catharina Ziekenhuis Eindhoven

    collaborator OTHER

  • Netherlands Cancer Institute - NKI

    collaborator UNKNOWN

  • Erasmus Medical Center

    lead OTHER

Principal Investigators

  • Pieter C van der Sluis, MD PhD · Erasmus MC, University Medical Center Rotterdam

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2027-10-01
Completion
2028-07-01

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07133490 on ClinicalTrials.gov